Concert Pharma Cash Flow - Annual (NASDAQ:CNCE)

Add to My Stocks
$13.75 $0 (0%) CNCE stock closing price Sep 20, 2018 (Closing)

The financial analysis of CNCE requires an investor to check the cash flows for Concert Pharma. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Concert Pharma profits one has to check the income statement and for Concert Pharma debt one has to check the balance sheet. Concert Pharma cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Concert Pharma had cash and cash equivalents of $40.55M at the beginning of the year and $27.66M at year end for 2017. Concert Pharma has a negative cash and cash equivalents change of $-12.89M.

View details of Concert Pharma cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow-1.08M1.29M1.65M-1.07M1.1M
Net Increase (Decrease) in Assets Liabilities-3.63M-0.77M-5.39M-1.52M16.79M-8.58M-9.54M
Cash From (used in) Discontinued Operations-------
Other Adjustments Net9.97M5.06M2.98M1.81M1.3M1.52M1.67M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.94M-0.77M-0.86M-0.8M-0.36M-0.46M-0.29M
Acquisition Disposition of Subsidiaires-------
Increase (Decrease) in Investments-120.36M-6.44M15.43M-43.64M-3.27M-0.73M23.19M
Other Cash Inflow (Outflow) from Investment Activities-------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares6.57M-48.83M87.58M---
Issuance (Repayment) of Debt Securities-1.08M--7.17M-8.18M-5.24M-0.33M-0.33M
Increase (Decrease) in Bank & Other Borrowings-------
Payment of Dividends & Other Cash Distributions-------
Other Cash from (used by) Financing Activities---0.18M-1.43M-2.02M12.5M7.3M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year40.55M92.51M13.39M9.63M7.49M22.94M11.14M
Cash & Equivalents at Year End27.66M40.55M92.51M13.39M9.63M7.49M22.94M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Concert Pharma stock price history provides insight into historical stock price fluctuations, and Concert Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Concert Pharma saw a positive change in Net Change in Cash and Cash Equivalents of $-12.89M in 2017. Apart from the Concert Pharma stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: Concert Pharma reported a positive operating cash flow of $102.92M for 2017 and has seen an increase from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash from investing stood at a negative value of $-121.3M for CNCE stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash flow from financing activities shows the flow of cash between Concert Pharma and its owners and creditors and was $5.49M for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Concert Pharma Cash Flow

FCF margin